期刊文献+

普拉固对颈动脉粥样硬化的影响 被引量:4

The Effect of Pravachol on Carotid Artery Atherosclerosis
下载PDF
导出
摘要 探讨普拉固对颈动脉粥样硬化的治疗及保护作用。将 12 0例颈动脉粥样硬化并高脂血症患者随机分为对照组和治疗组 ,治疗组给予普拉固 10mg/d治疗 ,并在治疗后 3、6及 12月以彩色超声多普勒检查双侧颈动脉及复查血脂 ,观察双侧颈动脉粥样硬化斑块的数量、类型、管腔内径及颈动脉后壁内膜中膜厚度 ,与对照组进行比较。结果发现 ,普拉固治疗 3月后能有效降低血浆总胆固醇、甘油三酯和低密度脂蛋白胆固醇水平 ,升高高密度脂蛋白胆固醇水平 ,且随着治疗时间的延长 ,其斑块数量减少、类型改变、管腔内径增大和内膜中膜厚度减小均有统计学意义 (P <0 .0 5或P <0 .0 1)。结果提示 ,普拉固能有效降低血脂水平 。 Aim To discuss the curative effect and protection of Pracachol on carotid atherosclerosis. Methods 120 patients with carotid atherosclerosis and hyperlipaemia were randomly divided into treatment group and control group. The treatment group were treated with Pracachol 10 mg/d and their carotids and lipid level were checked after 3, 6 and 12 months in order to compare with the control group on the numbers and types of their carotid atheromatous plaques,carotid inner diameters (D), the thickness between carotid intima-media thickness (IMT). Results 3 months' treatment with Pracachol can decrease total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDLC) level in plasme efficiently, and as the treatment prolonged, the decrease of plaques'numbers, the change of plaques' type and the dinilution of IMT all has Statistcal significance. Conclusions Pracachol can decrease the lipid level in plasma efficiently, and to some extent, it can improve and stabilize the carotid atheromatous plaque as well.
出处 《中国动脉硬化杂志》 CAS CSCD 2004年第5期593-595,共3页 Chinese Journal of Arteriosclerosis
关键词 内科学 普拉固对颈动脉硬化的影响 超声检测 动脉粥样硬化 血脂 普拉固 Atherosclerosis Serum Lipids Pracachol Carotid Inner Diameter Intima-Media Thickness
  • 相关文献

参考文献11

  • 1方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067
  • 2Hennerici M, Siegel NJ, Kappelman NB, et al. Detection of early arterosiclerotic lesions by duplex scanning of the carety. J Clin Ultrasound, 1984, 1 (2): 455
  • 3李素敏,郭恒怡,吴其夏.弱氧化型低密度脂蛋白的致动脉粥样硬化作用[J].中国动脉硬化杂志,2002,10(3):271-274. 被引量:23
  • 4Liao Jk, Shin WS, Lee WY, et al. oxidized low density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem, 1996, 270: 319-324
  • 5Andrews TC, Ballantyne CM, Hsia, et al. Acheving and maintaining national cholesterol education progrom low density lipoprotein cholesterol goals with five statins. Am J Med, 2001, 111 (3): 185-191
  • 6Girona J, La Viue AE, Sola R, et al. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol, 1999, 83: 846-851
  • 7乔木,王文,王佩合,张会东,孙瑞成,吴爱丽,刘力生.普伐他汀对SHRsp的脑保护作用及其可能机制的研究[J].高血压杂志,2002,10(6):561-566. 被引量:1
  • 8李凝旭,李庚山,李建军.他汀类药物调脂外的抗动脉粥样硬化作用机制[J].中国动脉硬化杂志,2002,10(3):268-270. 被引量:64
  • 9Frankel EN, Kanner J, German JB, et al. Inhibition of oxidation of human low density lipoprotein by substances in red wine. Lancet, 1993, 341: 454-457
  • 10Fukumoto Y, libby P, Rabkin E, et al. statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulition, 2001, 103 (7): 993-999

二级参考文献18

  • 1Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group[J].N Engl J Med,1995,333(20):1301-7.
  • 2Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study[J].JAMA,1998,279(20):1615-22.
  • 3Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)[J].Lancet,1994,344(8934):1383-9.
  • 4Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators[J].N Engl J Med,1996,335(14):1001-9.
  • 5The Long-Term Intervention with pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J].N Engl J Med,1998 Nov 5,339(19):1349-57.
  • 6Yamori Y. Development of the SHRs and of various spontaneous rat models, and their implications. In: Handbook of Hypertension, W. De Jong[J].Elsevier Amsterdam-New York-Oxford,1984, Vol 4: P224.
  • 7Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998,95(15):8880-5.
  • 8Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators[J].Circulation,1999,99(2):216-23.
  • 9Mohr JP, Albers GW, Amarenco P, et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Etiology of stroke[J].Stroke,1997,28(7):1501-6.
  • 10Navab M, Fogelman AM, Berliner JA, et al. Pathogenesis of atherosclerosis[J].Am J Cardiol,1995,76(9):18C-23C.

共引文献3145

同被引文献18

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部